Given the importance of the PI3K-AKT signaling pathway and the fact that PTEN was mutated or deleted in 40–60% of GBMs, it is necessary to explore effective combined treatment to boost the anti-glioma effect of PI3K inhibitors. This evidence concerns the gene PTEN and glioma.